耐碳青霉烯铜绿假单胞菌耐药机制的研究进展

高喆; 赵京明; 高喆; 赵京明

doi:10.12206/j.issn.2097-2024.202602016

[1]

DE PASCALE G, CORTEGIANI A, RINALDI M, et al. Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study[J]. Crit Care, 2025, 29(1): 32. doi: 10.1186/s13054-025-05266-1

[2]

秦洁, 邹成韵, 陶建敏, 等. 耐碳青霉烯类铜绿假单胞菌医院感染危险因素的Meta分析[J]. 国外医药(抗生素分册), 2022, 43(2): 87-95. doi: 10.3969/j.issn.1001-8751.2022.02.005

[3]

EID R, DABAR G, HANNA L R, et al. Comparison of antimicrobial resistance in Pseudomonas aeruginosa from intensive care and non-intensive care units and its impact on treatment decisions[J]. Sci Rep, 2025, 15: 11288. doi: 10.1038/s41598-025-90791-w

[4]

KARAMPATAKIS T, TSERGOULI K, BEHZADI P. Carbapenem-resistant Pseudomonas aeruginosa’s resistome: pan-genomic plasticity, the impact of transposable elements and jumping genes[J]. Antibiotics, 2025, 14(4): 353. doi: 10.3390/antibiotics14040353

[5]

XIE X Q, LIU Z, HUANG J Y, et al. Molecular epidemiology and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a hospital in Fujian, China[J]. Front Microbiol, 2024, 15: 1431154. doi: 10.3389/fmicb.2024.1431154

[6]

ZHOU L J, YAO J Y, ZHANG Y, et al. Global phylogeography and genetic characterization of carbapenem and ceftazidime-avibactam resistant KPC-33-producing Pseudomonas aeruginosa[J]. npj Antimicrob Resist, 2025, 3: 3. doi: 10.1038/s44259-024-00073-0

[7]

PHAM T T, MUNGARD N, PFENNIGWERTH N, et al. Challenges in laboratory diagnosis and antibiotic treatment options for a newly described Pseudomonas aeruginosa class A beta-lactamase type GES-62 strain[J]. GMS Infect Dis, 2025, 13: Doc09.

[8]

BONNIN R A, et al. Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases[J]. Clin Microbiol Rev, 2025, 38(3): e00129-e00123. doi: 10.1128/cmr.00129-23

[9]

QIAO X H, ZHANG H, XU Y, et al. Study on resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa to ceftazidime/avibactam in a certain region of China[J]. Front Cell Infect Microbiol, 2025, 15: 1643755. doi: 10.3389/fcimb.2025.1643755

[10]

KARLOWSKY J A, LOB S H, ESTABROOK M A, et al. Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21[J]. JAC Antimicrob Resist, 2023, 5(3): dlad080. doi: 10.1093/jacamr/dlad080

[11]

YIN L J, BAO Z H, HE L Y, et al. Virulence factors, molecular characteristics, and resistance mechanisms of carbapenem-resistant Pseudomonas aeruginosa isolated from pediatric patients in Shanghai, China[J]. BMC Microbiol, 2025, 25(1): 130. doi: 10.1186/s12866-025-03856-1

[12]

YANG Y, LI X, SUN L, et al. High level non-carbapenemase carbapenem resistance by overlaying mutations of mexR, oprD, and ftsI in Pseudomonas aeruginosa[J]. Microbiol Spectr, 2025, 13(1): e01398-e01324.

[13]

FRANDO A, PARSEK R S, OMAR J, et al. Modulation of thePseudomonas aeruginosaquorum sensing cascade by MexT-regulated factors[J]. mBio, 2025, 16(11): e02941-e02925. doi: 10.1101/2025.03.17.643737

[14]

KAVANAUGH L G, HINRICHSEN M E, DUNHAM C M, et al. Regulation, structure, and activity of the Pseudomonas aeruginosa MexXY efflux system[J]. Antimicrob Agents Chemother, 2025, 69(5): e01825-e01824.

[15]

CACCIOTTO P, BASCIU A, OLIVA F, et al. Molecular rationale for the impairment of the MexAB-OprM efflux pump by a single mutation in MexA[J]. Comput Struct Biotechnol J, 2022, 20: 252-260. doi: 10.1016/j.csbj.2021.11.042

[16]

韩美娟, 汤建华, 蒲洁琨, 等. 某院耐碳青霉烯类铜绿假单胞菌T3SS毒力因子携带、表达和毒力与耐药的相关性及分子流行病学研究[J]. 中国医院药学杂志, 2025, 45(4): 402-409. doi: 10.13286/j.1001-5213.2025.04.06

[17]

陈宇, 王林, 秦上尚. 铜绿假单胞菌的耐药性和耐药机制[J]. 中国农学通报, 2024, 40(12): 80-84.

[18]

周凯, 时翠销, 宋国滨, 等. 铜绿假单胞菌QS系统调控基因和毒力基因的携带、表达及与耐药的相关性[J]. 安徽医科大学学报, 2022, 57(5): 748-753. doi: 10.19405/j.cnki.issn1000-1492.2022.05.014

[19]

YANO H, NAKATA N, YAHARA K, et al. Specific variants in ftsI reduce carbapenem susceptibility in Pseudomonas aeruginosa[J]. Microbiol Spectr, 2025, 13(8): e01027-e01025.

[20]

YANO H, HAYASHI W, KAWAKAMI S, et al. Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan[J]. Antimicrob Agents Chemother, 2024, 68(5): e01669-e01623. doi: 10.1101/2023.12.17.572044

[21]

SALEEM M, SIDDIQUI M, UL HUDA H N, et al. Survival strategies of imipenem-resistant P. aeruginosa: a comparative analysis of surface-bound biofilms and unbound aggregates[J]. J Antibiot, 2025, 78(8): 500-510. doi: 10.1038/s41429-025-00834-7

[22]

MA Y P, AUNG T T, LAKSHMINARAYANAN R, et al. Biofilm formation and virulence potential of carbapenem-resistant Pseudomonas aeruginosa[J]. Lancet Microbe, 2023, 4(7): e489. doi: 10.1016/S2666-5247(23)00097-6

[23]

SENDRA E, FERNÁNDEZ-MUÑOZ A, ZAMORANO L, et al. Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective[J]. Infection, 2024, 52(4): 1235-1268. doi: 10.1007/s15010-024-02313-x

[24]

庞余, 刘向群. 铜绿假单胞菌生物膜形成能力及其耐药性关系的研究[J]. 临床医药文献电子杂志, 2019, 6(59): 30-34. doi: 10.16281/j.cnki.jocml.2019.59.015

[25]

刘岩, 潘蓓珍, 杨继飞, 等. 多重耐药铜绿假单胞菌群体感应相关基因表达及其对生物膜形成和耐药性的影响[J]. 吉林大学学报(医学版), 2025, 51(4): 921-928. doi: 10.13481/j.1671-587X.20250408

[26]

ALHADRAMI H A, SAYED A M, HASSAN H M, et al. Optimized peptide inhibitor Aqs1C targets LasR to disrupt quorum sensing and biofilm formation in Pseudomonas aeruginosa: Insights from MD simulations and in vitro studies[J]. Int J Biol Macromol, 2025, 300: 140119. doi: 10.1016/j.ijbiomac.2025.140119

[27]

ZHANG Y F, HAN K, CHANDLER C E, et al. Probing the sRNA regulatory landscape of P. aeruginosa: post-transcriptional control of determinants of pathogenicity and antibiotic susceptibility[J]. Mol Microbiol, 2017, 106(6): 919-937. doi: 10.1111/mmi.13857

[28]

LABORDA P, LOLLE S, HERNANDO-AMADO S, et al. Mutations in the efflux pump regulator MexZ shift tissue colonization by Pseudomonas aeruginosa to a state of antibiotic tolerance[J]. Nat Commun, 2024, 15: 2584. doi: 10.1038/s41467-024-46938-w

[29]

WU W Y, HUANG J H, XU Z L. Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications[J]. Microb Biotechnol, 2024, 17(5): e14487. doi: 10.1111/1751-7915.14487

[30]

MALECKA E M, BASSANI F, DENDOOVEN T, et al. Stabilization of Hfq-mediated translational repression by the co-repressor Crc in Pseudomonas aeruginosa[J]. Nucleic Acids Res, 2021, 49(12): 7075-7087. doi: 10.1093/nar/gkab510

[31]

BRÜGGEMANN H, MIGLIORINI L B, DE SALES R O, et al. Comparative genomics of nonoutbreak Pseudomonas aeruginosa strains underlines genome plasticity and geographic relatedness of the global clone ST235[J]. Genome Biol Evol, 2018, 10(7): 1852-1857. doi: 10.1093/gbe/evy139

[32]

LI Y, YANG Q, CHEN M H, et al. Decadal Evolution of KPC-related plasmids in Pseudomonas aeruginosa high-risk clone ST463 in Zhejiang, China[J]. Commun Biol, 2024, 7(1): 1646. doi: 10.1038/s42003-024-07337-5

[33]

曾玫, 夏君, 宗志勇, 等. 碳青霉烯类耐药革兰阴性菌感染的诊断、治疗及防控指南[J]. 中国感染与化疗杂志, 2024, 24(2): 135-151. doi: 10.16718/j.1009-7708.2024.02.002

[34]

YAMANO Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria[J]. Clin Infect Dis, 2019, 69(Supplement_7): S544-S551. doi: 10.1093/cid/ciz827